- Home
- CTO vs FTRE Comparison
CTO vs FTRE Comparison
Compare CTO & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- FTRE
- Stock Information
- Founded
- CTO 1902
- FTRE 1996
- Country
- CTO United States
- FTRE United States
- Employees
- CTO N/A
- FTRE N/A
- Industry
- CTO Real Estate Investment Trusts
- FTRE Medical Specialities
- Sector
- CTO Real Estate
- FTRE Health Care
- Exchange
- CTO Nasdaq
- FTRE Nasdaq
- Market Cap
- CTO 568.5M
- FTRE 468.1M
- IPO Year
- CTO N/A
- FTRE N/A
- Fundamental
- Price
- CTO $16.36
- FTRE $6.20
- Analyst Decision
- CTO Strong Buy
- FTRE Hold
- Analyst Count
- CTO 3
- FTRE 11
- Target Price
- CTO $22.00
- FTRE $16.00
- AVG Volume (30 Days)
- CTO 282.3K
- FTRE 1.8M
- Earning Date
- CTO 07-29-2025
- FTRE 08-06-2025
- Dividend Yield
- CTO 9.31%
- FTRE N/A
- EPS Growth
- CTO N/A
- FTRE N/A
- EPS
- CTO N/A
- FTRE N/A
- Revenue
- CTO $140,996,000.00
- FTRE $2,685,600,000.00
- Revenue This Year
- CTO $19.01
- FTRE N/A
- Revenue Next Year
- CTO $7.38
- FTRE $0.97
- P/E Ratio
- CTO N/A
- FTRE N/A
- Revenue Growth
- CTO 22.26
- FTRE N/A
- 52 Week Low
- CTO $16.12
- FTRE $3.97
- 52 Week High
- CTO $21.15
- FTRE $27.99
- Technical
- Relative Strength Index (RSI)
- CTO 31.00
- FTRE 58.57
- Support Level
- CTO $17.31
- FTRE $6.17
- Resistance Level
- CTO $17.74
- FTRE $6.90
- Average True Range (ATR)
- CTO 0.34
- FTRE 0.47
- MACD
- CTO -0.04
- FTRE 0.16
- Stochastic Oscillator
- CTO 2.07
- FTRE 71.37
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.